Last reviewed · How we verify
Hepar-P
At a glance
| Generic name | Hepar-P |
|---|---|
| Sponsor | Nova Laboratories Sdn Bhd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH (PHASE1, PHASE2)
- PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC) (NA)
- Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy (NA)
- A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis (NA)
- Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controlled Trial (PHASE2)
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery (PHASE3)
- A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hepar-P CI brief — competitive landscape report
- Hepar-P updates RSS · CI watch RSS
- Nova Laboratories Sdn Bhd portfolio CI